Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KPTI
stocks logo

KPTI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
35.84M
+17.34%
-2.170
-39.72%
35.50M
+18.28%
-2.055
-25.81%
36.82M
-2.94%
-1.960
-54.63%
Estimates Revision
The market is revising No Change the revenue expectations for Karyopharm Therapeutics Inc. (KPTI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -10.45%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+20.82%
In Past 3 Month
Stock Price
Go Down
down Image
-10.45%
In Past 3 Month
Wall Street analysts forecast KPTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPTI is 13.83 USD with a low forecast of 6.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast KPTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPTI is 13.83 USD with a low forecast of 6.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 5.910
sliders
Low
6.00
Averages
13.83
High
21.00
Current: 5.910
sliders
Low
6.00
Averages
13.83
High
21.00
RBC Capital
Brian Abrahams
Outperform
to
NULL
downgrade
$30 -> $19
2025-11-04
Reason
RBC Capital
Brian Abrahams
Price Target
$30 -> $19
2025-11-04
downgrade
Outperform
to
NULL
Reason
RBC Capital analyst Brian Abrahams lowered the firm's price target on Karyopharm to $19 from $30 and keeps an Outperform rating on the shares. The company reported a solid quarter for Xpovio sales, while the reduction of financing overhangs, and MF timelines intact for March 2026 make for a favorable risk/reward setup, the analyst tells investors in a research note. RBC adds however that its reduced price target reflects the recent financing transactions.
Baird
Outperform -> NULL
downgrade
$42 -> $25
2025-08-12
Reason
Baird
Price Target
$42 -> $25
2025-08-12
downgrade
Outperform -> NULL
Reason
Baird lowered the firm's price target on Karyopharm to $25 from $42 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which showed its MF Phase 3 enrollment is early complete.
H.C. Wainwright
Robert Burns
Buy -> Neutral
downgrade
2025-07-16
Reason
H.C. Wainwright
Robert Burns
Price Target
2025-07-16
downgrade
Buy -> Neutral
Reason
H.C. Wainwright analyst Robert Burns downgraded Karyopharm to Neutral from Buy without a price target. The firm has solvency concerns, saying the company's recent failure to raise capital raise is a "significant concern." H.C. Wainwright also also takes into account that the top-line results from the Phase 3 trial evaluating selinexor in JAKi-naive myelofibrosis are not expected until Q1 of 2026.
H.C. Wainwright
Robert Burns
initiated
$27
2025-07-11
Reason
H.C. Wainwright
Robert Burns
Price Target
$27
2025-07-11
initiated
Reason
H.C. Wainwright analyst Robert Burns assumed coverage of Karyopharm with a Buy rating and $27 price target. The firm believes the company's investigation into maintenance therapy for the solid tumor indication is "risk-mitigated." Karyopharmhas "several significant data catalysts" that could drive investor interest, the analyst tells investors in a research note.
Barclays
Overweight
maintain
$5 -> $10
2025-05-13
Reason
Barclays
Price Target
$5 -> $10
2025-05-13
maintain
Overweight
Reason
Barclays raised the firm's price target on Karyopharm to $10 from $5 and keeps an Overweight rating on the shares. The company's Q1 selinexor revenue of $21.1M was below consensus of $28.7M, but the key focus for investors is on pivotal myelofibrosis data in late 2025/early 2026, the analyst tells investors in a research note. The firm adjusted its model to account for the recent stock split.
Baird
Colleen Kusy
Outperform -> Outperform
downgrade
$54 -> $42
2025-05-13
Reason
Baird
Colleen Kusy
Price Target
$54 -> $42
2025-05-13
downgrade
Outperform -> Outperform
Reason
Baird analyst Colleen Kusy lowered the firm's price target on Karyopharm to $42 from $54 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where the company updated its pipeline progress.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Karyopharm Therapeutics Inc (KPTI.O) is -0.73, compared to its 5-year average forward P/E of -2.27. For a more detailed relative valuation and DCF analysis to assess Karyopharm Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.27
Current PE
-0.73
Overvalued PE
-0.70
Undervalued PE
-3.83

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-2.39
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.41
Undervalued EV/EBITDA
-4.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2.28
Current PS
0.00
Overvalued PS
4.40
Undervalued PS
0.17
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

KPTI News & Events

Events Timeline

(ET)
2025-11-05
08:45:01
Significant Borrowing Rate Hikes Among Liquid Assets
select
2025-11-03 (ET)
2025-11-03
07:08:08
Karyopharm projects FY25 revenue between $140M and $155M, with consensus at $150.22M.
select
2025-11-03
07:06:28
Karyopharm Announces Q3 Earnings Per Share of $3.82, Exceeding Consensus Estimate of $3.25
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
1.0
12-01PRnewswire
Karyopharm to Participate in Piper Sandler Healthcare Conference in New York
  • Management Participation: Karyopharm Therapeutics' senior management team will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025, showcasing the company's innovations in cancer therapies.
  • Live Webcast: The fireside chat will be accessible via a live webcast on the company's website under the 'Events & Presentations' section, allowing investors to engage in real-time and access a replay post-event, enhancing investor relations.
  • Industry Leadership: Karyopharm focuses on developing oral compounds targeting nuclear export dysregulation, with its lead product XPOVIO® (selinexor) approved in the U.S. and marketed across multiple oncology indications, underscoring its leadership in cancer treatment.
  • Global Market Expansion: The company has received regulatory approvals for XPOVIO® in 50 territories, including the EU and China, indicating its potential for global market expansion and commitment to cancer patients.
[object Object]
Preview
5.0
11-04PRnewswire
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • RSU Grant Announcement: Karyopharm Therapeutics granted 800 restricted stock units (RSUs) to a newly-hired employee as part of their 2022 Inducement Stock Incentive Plan, effective October 31, 2025.

  • Vesting Schedule: The RSUs will vest over three years, with one-third of the shares vesting on each anniversary of the grant date, contingent on the employee's continued service.

  • Company Overview: Karyopharm Therapeutics is focused on developing novel cancer therapies, particularly through its lead compound, XPOVIO (selinexor), which is approved in the U.S. and several international markets.

  • Pipeline Focus: The company targets high unmet need cancers, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

[object Object]
Preview
9.5
11-03SeekingAlpha
Karyopharm Therapeutics Reports GAAP EPS of -$3.82, Falling Short by $0.30; Revenue of $44.04M Exceeds Expectations by $1.63M

  • Earnings Report: Karyopharm Therapeutics (KPTI) reported a Q3 GAAP EPS of -$3.82, missing expectations by $0.30, while revenue reached $44.04 million, a 13.6% year-over-year increase, beating estimates by $1.63 million.

  • Product Revenue: The U.S. net product revenue for XPOVIO (selinexor) was $32.0 million, reflecting an 8.5% increase compared to the same quarter in 2024.

  • Revenue Guidance: The company reaffirmed its full-year 2025 total revenue guidance of $140 million to $155 million, slightly below the consensus of $150.22 million, and provided a net product revenue guidance for XPOVIO of $110 million to $120 million.

  • Financing Update: Karyopharm secured $100 million in financing to extend its cash runway into Q2 2026, which positively impacted its stock performance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Karyopharm Therapeutics Inc (KPTI) stock price today?

The current price of KPTI is 5.91 USD — it has increased 8.24 % in the last trading day.

arrow icon

What is Karyopharm Therapeutics Inc (KPTI)'s business?

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

arrow icon

What is the price predicton of KPTI Stock?

Wall Street analysts forecast KPTI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KPTI is 13.83 USD with a low forecast of 6.00 USD and a high forecast of 21.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Karyopharm Therapeutics Inc (KPTI)'s revenue for the last quarter?

Karyopharm Therapeutics Inc revenue for the last quarter amounts to 44.04M USD, increased 13.57 % YoY.

arrow icon

What is Karyopharm Therapeutics Inc (KPTI)'s earnings per share (EPS) for the last quarter?

Karyopharm Therapeutics Inc. EPS for the last quarter amounts to -3.82 USD, decreased -0.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for Karyopharm Therapeutics Inc (KPTI)'s fundamentals?

The market is revising No Change the revenue expectations for Karyopharm Therapeutics Inc. (KPTI) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -10.45%.
arrow icon

How many employees does Karyopharm Therapeutics Inc (KPTI). have?

Karyopharm Therapeutics Inc (KPTI) has 279 emplpoyees as of December 05 2025.

arrow icon

What is Karyopharm Therapeutics Inc (KPTI) market cap?

Today KPTI has the market capitalization of 100.94M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free